29 - What's New in Fungal Therapeutics and Diagnostics in Transplant?

Thursday, October 20, 2022

10:30 AM – 11:45 AM US ET

Location: 201

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Lena Heung, MD, PhD

Assistant Professor
Cedars-Sinai Medical Center

Disclosure(s): 3M: Stocks/Bonds (Ongoing); Kimberly-Clark: Stocks/Bonds (Ongoing); Procter & Gamble: Stocks/Bonds (Ongoing)
Maricar Malinis, MD

Associate Professor of Medicine and Transplant (Surgery), Medical Director of Transplant and Oncology ID
Yale School of Medicine
New Haven, CT, United States

Disclosure(s): Aicuris: Primary investigator of clinical trial at Yale site, renumeration goes to institution (Ongoing); Takeda: primary investigator of clinical trial at yale site, renumeration goes to institution (Ongoing)

Faculty(s)

Gregory Eschenauer, PharmD

Clinical Associate Professor
University of Michigan
Ann Arbor, MI, United States

Disclosure(s): Wolters-Kluwer: Advisor/Consultant (Ongoing)

Slides
Margaret Powers-Fletcher, PhD

Associate Professor, Infectious Diseases Division, Department of Internal Medicine
Microbiology, Pathology and Molecular Diagnostics
University of Cincinnati
Cincinnati, OH, United States

Disclosure(s): Molecular Research Center: Grant/Research Support (Terminated); OpGen: Grant/Research Support (Ongoing)

Slides
Mariana Castanheira, PhD

Chief Scientific Officer
JMI Laboratories
North Liberty, Iowa, United States

Disclosure(s): No financial relationships to disclose

Slides

Disclosure(s):

Lena Heung, MD, PhD: 3M: Stocks/Bonds (Ongoing); Kimberly-Clark: Stocks/Bonds (Ongoing); Procter & Gamble: Stocks/Bonds (Ongoing)

Maricar F. Malinis, MD: Aicuris: Primary investigator of clinical trial at Yale site, renumeration goes to institution (Ongoing); Takeda: primary investigator of clinical trial at yale site, renumeration goes to institution (Ongoing)

Gregory Eschenauer, PharmD: Wolters-Kluwer: Advisor/Consultant (Ongoing)

Margaret Powers-Fletcher, PhD: Molecular Research Center: Grant/Research Support (Terminated); OpGen: Grant/Research Support (Ongoing)

Mariana Castanheira, PhD: No financial relationships to disclose

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss novel antifungal therapies, mechanisms of action, current data and potential applications for clinical care;
summarize current and novel fungal diagnostics, including their advantages, disadvantages and use in the care of immunocompromised hosts;
describe current methods for fungal susceptibility testing, including CLSI guidelines and ongoing challenges with susceptibility testing in fungi

Presentations:

10:30 AM – 10:55 AM US ET

Novel Antifungals in the Pipeline
Speaker: Gregory Eschenauer, PharmD – University of Michigan
10:55 AM – 11:20 AM US ET

The Fungal Diagnostics Frontier
Speaker: Margaret Powers-Fletcher, PhD – University of Cincinnati
11:20 AM – 11:45 AM US ET

Antifungal Susceptibility Testing Challenges
Speaker: Mariana Castanheira, PhD – JMI Laboratories